The following section evaluates ghrelin's evidence for various health outcomes, organized by tier level and supported by specific research findings.
Ghrelin is recognized as a natural hunger hormone that increases during weight loss, which paradoxically makes fat loss maintenance more difficult. However, the evidence does not support that modulating ghrelin itself produces fat loss in humans.
Research consistently demonstrates that weight loss via calorie restriction increases total ghrelin levels significantly. A meta-analysis across randomized controlled trials and observational studies (n>6000 participants) found a standardized mean difference (SMD) of 0.24–0.55 for total ghrelin increases. These elevated ghrelin levels represent a compensatory response that can persist up to one year post-weight loss, creating metabolic resistance to sustained fat loss.
Notably, high-protein diets (30% protein) reduce ad libitum caloric intake by 441 ± 63 kilocalories per day and body weight by 4.9 ± 0.5 kg despite a significantly increased ghrelin area-under-the-curve (AUC), demonstrating that ghrelin changes alone do not determine satiety or weight loss success.
Bottom line: Ghrelin dynamics change during weight loss, but lowering ghrelin has not been proven effective for actual fat loss in humans.
Ghrelin shows no proven efficacy for muscle growth in humans. While unacylated ghrelin demonstrated protective effects against age-related muscle loss in mice—preserving 20-30% of muscle mass and preventing a 30% loss of specific muscle force over ten months—human evidence is absent.
In humans, acylated ghrelin levels increase with weight loss (SMD: 0.24-0.55 across multiple studies, n=19 RCTs and 108 non-RCTs), indicating a compensatory appetite response rather than anabolic signaling. The primary mechanism of acylated ghrelin is appetite stimulation and weight gain, not muscle protein synthesis or anabolism.
Bottom line: No human evidence supports ghrelin for muscle growth; animal studies on unacylated ghrelin do not translate to efficacy data in humans.
Ghrelin shows promise for injury recovery in animal models, with demonstrated effects on wound healing and gastrointestinal tissue repair. However, human efficacy remains unproven, with only mechanistic reviews and one small human RCT examining bone markers.
In rats with colonic anastomosis, ghrelin administered at 10 ng/kg/day for seven days significantly increased bursting pressure and hydroxyproline levels compared to saline control, while also reducing adhesion formation scores (n=10/group). In another animal study, ghrelin accelerated healing of chronic gastric ulcers in rats by reducing ulcer area and increasing blood flow at ulcer margins compared to control.
Bottom line: Animal evidence suggests potential benefits for tissue repair, but human clinical efficacy for injury recovery is unproven.
Ghrelin shows promising anti-inflammatory effects on cartilage degradation in laboratory studies, but human efficacy for joint health is unproven. No clinical trials demonstrate that ghrelin supplementation improves joint function or arthritis symptoms.
In vitro studies show that ghrelin reduces IL-1β-induced expression of matrix metalloproteinases (MMP-3, MMP-13) and ADAMTS enzymes in a concentration-dependent manner, ameliorating type II collagen and aggrecan degradation in human chondrocytes. Additionally, ghrelin inhibits IRF-1 expression by inactivating the JAK2/STAT3 pathway in chondrocytes without affecting p38 activation.
Bottom line: Mechanistic evidence suggests anti-inflammatory cartilage protection, but no human trials demonstrate clinical joint health benefits.
Ghrelin shows mechanistic links to inflammation through multiple pathways, but direct evidence that ghrelin supplementation reduces inflammation in humans is absent. Existing human studies focus on ghrelin's role in appetite and metabolism rather than inflammatory outcomes.
In inflammatory bowel disease (IBD), serum ghrelin levels serve as biomarkers distinguishing active disease from remission phases, suggesting a regulatory role in inflammatory processes. In mechanistic reviews, ghrelin reduces intestinal barrier damage in sepsis by inhibiting inflammatory responses and enhancing gastrointestinal blood flow.
Bottom line: Biomarker and mechanistic evidence suggests anti-inflammatory potential, but human supplementation trials are lacking.
Ghrelin shows plausible cognitive benefits in animal models—particularly for memory formation and synaptic plasticity in the hippocampus—but human evidence is minimal and indirect. No human RCTs have tested ghrelin directly for cognition; the only human study measured brain activity changes (fMRI) related to appetite regions, not actual cognitive performance.
In rodent studies, acylated ghrelin enhances spatial memory, recognition memory, contextual fear memory, and passive avoidance learning through hippocampal mechanisms. Additionally, GHSR1a-dopamine D1 receptor heteromers in the hippocampus promote synaptic plasticity and memory formation; reduction in favor of GHSR1a-amyloid-beta complexes correlates with Alzheimer's disease pathology.
Bottom line: Animal evidence is promising, but no human clinical trials demonstrate cognitive benefits from ghrelin supplementation.
Ghrelin shows biological associations with mood and stress in humans, with elevated levels observed during acute stress and in depression. However, no randomized controlled trials demonstrate that ghrelin supplementation actually improves mood or reduces stress.
Acute laboratory stress significantly increased ghrelin levels within five minutes (effect size ES=0.29, 95% CI 0.10-0.48) in a meta-analysis of ten human studies (n=348 total). The effect was more pronounced and prolonged in obese versus non-obese individuals (ES=0.51 vs. non-significant after five minutes).
Ghrelin levels were independent predictors of frailty in older adults (n=85, cross-sectional observational study); frail patients had significantly lower ghrelin, NPY, and AgRP compared to non-frail peers.
Bottom line: Ghrelin correlates with stress and mood biomarkers, but no intervention trials demonstrate mood or stress improvement from supplementation.
Ghrelin levels change with sleep duration and circadian alignment in humans, with short sleep associated with elevated ghrelin and increased hunger. However, no studies demonstrate that directly administering or supplementing ghrelin improves sleep quality or sleep outcomes.
Sleep restriction increased ghrelin levels by 28% in healthy young men (n=12, RCT, p<0.04) with concurrent 24% increase in hunger and 23% increase in appetite. Short sleep duration (5 hours versus 8 hours) was associated with 14.9% higher ghrelin in polysomnographic sleep, independent of BMI (n=1024, observational study, p=0.008).
Bottom line: Ghrelin changes correlate with sleep restriction, but no evidence supports ghrelin supplementation for sleep improvement.
Ghrelin shows biological effects on aging-related muscle loss and appetite regulation in humans, but evidence for longevity benefits is limited to mechanistic studies and observational findings. No human RCTs directly demonstrate that ghrelin supplementation extends lifespan or healthspan.
Unacylated ghrelin partially protected against age-related muscle loss (preserving 20-30% of muscle mass) and prevented 30% decline in specific muscle force in old mice over ten months. In humans, older adults with anorexia of aging showed paradoxically elevated fasting acyl-ghrelin (621 ± 307 pg/mL versus 353 ± 166 pg/mL in young adults, p=0.047) and greater suppression after feeding, suggesting ghrelin resistance rather than deficiency (n=37 humans, observational).
Bottom line: Animal evidence for anti-aging effects exists, but human longevity data are absent.
Ghrelin shows anti-inflammatory and immunomodulatory properties in preclinical and animal models, with emerging evidence from small human observational studies suggesting potential immune benefits. However, no robust human RCTs demonstrating efficacy for immune function exist.
In hybrid tilapia infected with Aeromonas hydrophila, ghrelin injection at 1.0 ng/g body weight increased survival rate to 66.66% versus 13.33% in untreated infected controls, with reduced liver and spleen pathology. COVID-19 patients (n=53) showed significantly elevated ghrelin concentrations six months post-infection compared to healthy controls (n=87), with sex-dependent differences and negative correlation with cortisol levels, suggesting a potential protective anti-inflammatory role.
Bottom line: Animal and observational evidence suggests immunomodulatory potential, but no human intervention trials have been conducted.
Ghrelin is a natural hormone that stimulates appetite and food intake in humans, but there is no evidence that supplementing with ghrelin improves energy levels or energy-related outcomes. The research shows ghrelin's role in appetite regulation, not energy enhancement.
Sprint interval training suppressed acylated ghrelin at 0, 30, 60, and 120 minutes post-exercise compared to control (p<0.080, d>0.56), with greater suppression than moderate-intensity continuous training. However, suppression of ghrelin during exercise is distinct from energy improvement.
Bottom line: No evidence supports ghrelin supplementation for energy enhancement.
Ghrelin shows no proven efficacy for skin or hair health. While ghrelin levels correlate with some metabolic markers, there is no evidence that ghrelin supplementation or modulation improves skin or hair outcomes.
One observational study found lower serum ghrelin in acne patients (n=50), with acne severity showing a significant effect on ghrelin level. A positive correlation between hair zinc and serum ghrelin was noted in children (n=25), but the correlation was weak and not statistically significant in final analysis.
Bottom line: No human trials support ghrelin for skin or hair health.
Ghrelin is a gut hormone that increases during weight loss and fasting, but evidence does not demonstrate that ghrelin supplementation or modulation improves gut health. Most research examines ghrelin's role in appetite and metabolism rather than direct gut health outcomes.
Weight loss induces consistent increases in total ghrelin (SMD 0.55 in RCTs, 95% CI 0.07–1.04; SMD 0.24 in observational studies, 95% CI 0.14–0.35) across a meta-analysis of 127 studies, yet acylated ghrelin decreased in RCTs (SMD –0.58) and increased in observational studies (SMD 0.15).
Bottom line: Ghrelin is part of natural gut physiology, but supplementation evidence for gut health is absent.
Ghrelin shows cardioprotective effects in mechanistic and animal studies, but human evidence for heart health is limited to small trials and observational data. No large-scale human RCTs demonstrate that ghrelin supplementation improves clinical cardiovascular outcomes.
Ghrelin receptors (GHSR-1a) are widely distributed in cardiovascular tissues including the heart and vasculature, suggesting direct cardioprotective potential. Exogenous ghrelin administration improved cardiac function and reduced arrhythmia incidence in animal models of myocardial infarction.
Bottom line: Mechanistic and animal evidence exists, but human clinical trials are lacking.
Ghrelin shows hepatoprotective potential in non-alcoholic fatty liver disease (NAFLD) based on mechanistic reviews and limited human observational data, but no randomized controlled trials in humans have demonstrated efficacy for liver health.
In liver cirrhosis patients (n=60), both acylated and total ghrelin were significantly elevated compared to healthy controls (n=20), with acylated ghrelin levels significantly higher in advanced (Child C) versus mild-moderate (Child A/B) cirrhosis. Ghrelin and leptin showed inverse correlation in cirrhotic patients, confirming ghrelin's role as a physiological counterpart to leptin in hepatic metabolism.
Bottom line: Observational associations exist, but no intervention trials demonstrate liver health benefits.
Ghrelin is a well-characterized appetite-regulating hormone with proven physiological effects on hunger and energy balance in humans, but evidence that supplementing or manipulating ghrelin improves hormonal health outcomes is limited to mechanistic studies and observational findings.
Weight loss via calorie restriction or exercise increases total ghrelin (RCTs: SMD 0.55, 95% CI 0.07-1.04; non-RCTs: SMD 0.24, 95% CI 0.14-0.35) in a meta-analysis of 127 studies (n=6030 participants). Late eating significantly increased 24-hour ghrelin:leptin ratio (p=0.006) and waketime ghrelin:leptin ratio (p<0.0001) in a randomized crossover trial (n=14 adults).
Bottom line: Ghrelin plays a defined role in natural hormonal balance, but supplementation for hormonal optimization is unproven.
Ghrelin's relationship to sexual health has not been directly studied in humans. Available evidence only explores ghrelin's connections to reproductive hormones, fertility markers, and metabolic factors that indirectly relate to sexual function, with no direct efficacy data for sexual health outcomes.
Ghrelin levels positively correlate with total testosterone (r=0.5, p=0.039) and bioavailable testosterone (r=0.719, p=0.0011) in men (n=19, observational study). In postmenopausal women (n=14), ghrelin strongly correlates with total testosterone (r=0.7, p=0.01) and bioavailable testosterone (r=0.821, p=0.001).
Bottom line: Correlations with testosterone exist, but no direct evidence supports ghrelin supplementation for sexual health.
Ghrelin suppression during acute exercise is well-documented in humans, but evidence that this translates to meaningful athletic performance improvements is absent. Studies show exercise reduces ghrelin and hunger acutely, yet this has not been linked to performance gains.
Acute exercise suppresses acylated ghrelin with a moderate effect size (ES = -0.73) in overweight/obese adults (n=34 trials). Short-term acute aerobic exercise did not affect total ghrelin regardless of intensity, but long/very-long aerobic exercise increased total ghrelin mainly in overweight/obese individuals (meta-analysis of 61 studies).
Bottom line: Exercise modulates ghrelin, but no evidence demonstrates performance improvement from ghrelin supplementation.
Ghrelin is administered by injection only. Standard research and clinical dosing protocols are:
Standard Dose: 1-3 micrograms per kilogram (mcg/kg) body weight, administered once to twice daily.
For a 70 kg individual, this translates to 70-210 mc